Incyte Corp
INCYHealthcare|Biotechnology|USA
$93.59
-1.27 (-1.34%)
DCF (FCF)
$55.64
Tangible Book
$24.78
Graham Number
$61.53
Earnings Power
$50.38
Upcoming Data Readouts (100)
Sep 2026
Est. completion
P3Diffuse Large B-cell Lymphoma
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092n=899
Sep 2026
Est. completion
P1Breast Cancer
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NCT06488378n=20
Sep 2026
Est. completion
P1Acute Lymphoblastic Leukemia
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT03571321n=15
Sep 2026
Est. completion
P1Graft Vs Host Disease
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
NCT06008808n=41
Sep 2026
Est. completion
P2Cutaneous Squamous Cell Carcinoma
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
NCT05888844n=63
Sep 2026
Est. completion
P1P2Soft Tissue Sarcoma
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
NCT04577014n=98
Sep 2026
Est. completion
P2P3Acute Lymphoblastic Leukemia
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03117751n=790
Oct 2026
Est. completion
P2Hidradenitis Suppurativa
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
NCT04414514n=24
Oct 2026
Est. completion
P3Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211n=550
Oct 2026
Est. completion
P3Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225n=550
Oct 2026
Est. completion
P3Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952n=330
Oct 2026
Est. completion
P3Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965n=330
Dec 2026
Est. completion
P2TNBC - Triple-Negative Breast Cancer
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT05491226n=35
Dec 2026
Est. completion
P1Hidradenitis Suppurativa
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575n=24
Dec 2026
Est. completion
P3Hidradenitis Suppurativa (HS)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999n=617
Dec 2026
Est. completion
P1Acute Myeloid Leukemia
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT04659616n=32
Dec 2026
Est. completion
P1P2Non Hodgkins Lymphoma
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
NCT04661007n=72
Dec 2026
Est. completion
P2Advanced Pancreatic Carcinoma
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
NCT06906562n=40
Dec 2026
Est. completion
P2Grade 3b Follicular Lymphoma
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
NCT05890352n=227
Dec 2026
Est. completion
Early P1Lymphoma, B-Cell
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT04161248n=18
Awaiting Results (29)
Trials past primary completion date but still active — data readout may be imminent.
Jul 2026
P2
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
NCT05879822Jun 2026
P2
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
NCT04640025Jun 2026
P1
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
NCT02494882May 2026
P1P2
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
NCT06873789Apr 2026
P2
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NCT04463771Apr 2026
P1
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
NCT05743595Apr 2026
P3
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
NCT05429268Mar 2026
P3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471